European Equities Traded in the US as American Depositary Receipts Close Bearish Week on High Note Friday

MT Newswires Live11-01

European equities traded in the US as American depositary receipts were rallying late Friday morning, rising 0.98% to 1,367.20 on the S&P Europe Select ADR Index, but were still down 1.4% for the week.

From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and semiconductor company Sequans Communications (SQNS), which rose 5.8% and 3.3%, respectively. They were followed by financial services companies Banco Santander (SAN) and Banco Bilbao Vizcaya Argentaria (BBVA), which were up 2.4% and 2.1%, respectively.

The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and biotech firm BioNTech (BNTX), which fell 4.7% and 1.4%, respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and internet advertising firm Criteo (CRTO), which were off 0.8% and 0.7%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and pharmaceutical company Silence Therapeutics (SLN), which increased 5.4% and 3.6%, respectively. They were followed by financial services company Lloyds Banking Group (LYG) and biopharmaceutical company Amarin Corporation (AMRN), which rose 2.9% and 2.8%, respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB), which fell 3.4%, followed by biopharmaceutical company Akari Therapeutics (AKTX) and cruise line operator Carnival (CUK) were off 0.2% and 0.1%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment